MX2023010125A - Inhibidores del sarcomero cardiaco. - Google Patents

Inhibidores del sarcomero cardiaco.

Info

Publication number
MX2023010125A
MX2023010125A MX2023010125A MX2023010125A MX2023010125A MX 2023010125 A MX2023010125 A MX 2023010125A MX 2023010125 A MX2023010125 A MX 2023010125A MX 2023010125 A MX2023010125 A MX 2023010125A MX 2023010125 A MX2023010125 A MX 2023010125A
Authority
MX
Mexico
Prior art keywords
sup
pharmaceutically acceptable
cardiac sarcomere
inhibitors
tautomer
Prior art date
Application number
MX2023010125A
Other languages
English (en)
Inventor
Chihyuan Chuang
Bradley P Morgan
Luke W Ashcraft
Justin Ho
Alfredo GARCÍA
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MX2023010125A publication Critical patent/MX2023010125A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de la Fórmula (I): (ver Fórmula) (I), o un estereoisómero o tautómero de los mismos, o una sal farmacéuticamente aceptable de cualquiera de los precedentes, en donde R1, R2, R3, y R4 han sido definidos en la presente. Además se proporciona una composición farmacéuticamente aceptable que comprende un compuesto de la Fórmula (I), o un estereoisómero o tautómero del mismo, o una sal farmacéuticamente aceptable de cualquiera de los precedentes. Además se proporcionan métodos de uso de un compuesto de la Fórmula (I), o un estereoisómero o tautómero del mismo, o una sal farmacéuticamente aceptable de cualquiera de los precedentes.
MX2023010125A 2021-03-04 2022-03-03 Inhibidores del sarcomero cardiaco. MX2023010125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163156853P 2021-03-04 2021-03-04
PCT/US2022/018725 WO2022187501A1 (en) 2021-03-04 2022-03-03 Cardiac sarcomere inhibitors

Publications (1)

Publication Number Publication Date
MX2023010125A true MX2023010125A (es) 2023-09-11

Family

ID=80937093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010125A MX2023010125A (es) 2021-03-04 2022-03-03 Inhibidores del sarcomero cardiaco.

Country Status (14)

Country Link
US (1) US11919909B2 (es)
EP (1) EP4301760A1 (es)
JP (1) JP2024508526A (es)
KR (1) KR20240015622A (es)
CN (1) CN117083275A (es)
AR (1) AR125026A1 (es)
AU (1) AU2022229390A1 (es)
BR (1) BR112023017461A2 (es)
CA (1) CA3209557A1 (es)
CL (1) CL2023002616A1 (es)
IL (1) IL305628A (es)
MX (1) MX2023010125A (es)
TW (1) TW202302594A (es)
WO (1) WO2022187501A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
BR112021003496A2 (pt) 2018-08-31 2021-05-18 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤
WO2024050539A1 (en) * 2022-09-02 2024-03-07 Cytokinetics, Incorporated Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO2003059265A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
ES2378620T3 (es) 2003-03-27 2012-04-16 Cytokinetics, Inc. Sulfonamidas para el tratamiento de insuficiencia cardiaca congestiva, sus composiciones y usos.
JPWO2004094424A1 (ja) 2003-04-21 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその用途
TWI359812B (en) 2004-06-17 2012-03-11 Cytokinetics Inc Compounds, compositions and methods
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
WO2006116150A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
JP5659224B2 (ja) 2009-05-15 2015-01-28 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリールピリジン
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
NZ628910A (en) 2012-01-20 2016-02-26 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
TN2015000553A1 (en) 2013-06-21 2017-04-06 Myokardia Inc Pyrimidinedione compounds against cardiac conditions
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
CN104539229A (zh) 2014-12-26 2015-04-22 金海新源电气江苏有限公司 一种太阳能光伏支架
UA119905C2 (uk) 2015-01-22 2019-08-27 Міокардіа, Інк. Сполуки 4-метилсульфонілзаміщеної піперидинсечовини для лікування дилатаційної кардіоміопатії (dcm)
EP3390397A1 (en) 2015-12-17 2018-10-24 Syngenta Participations AG Microbiocidal oxadiazole derivatives
WO2017103223A1 (en) 2015-12-18 2017-06-22 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
AU2017257151A1 (en) 2016-04-29 2018-11-15 Board Of Regents, The University Of Texas System Sigma receptor binders
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
JP6681517B2 (ja) 2016-09-27 2020-04-15 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
US20200000822A1 (en) 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
AU2018311974B2 (en) 2017-08-04 2024-03-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy
MX2020007532A (es) 2018-01-19 2020-09-09 Cytokinetics Inc Inhibidores de sarcomero cardiaco.
HUE057970T2 (hu) 2018-03-08 2022-06-28 Incyte Corp Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP2021529746A (ja) 2018-06-26 2021-11-04 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
BR112021003496A2 (pt) 2018-08-31 2021-05-18 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco
CR20210099A (es) 2018-08-31 2021-06-24 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapèuticos
EP3999180B1 (en) 2019-07-17 2024-05-08 Cytokinetics, Inc. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
US20220265612A1 (en) 2019-07-17 2022-08-25 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
JP2023501453A (ja) 2019-11-10 2023-01-18 マイオカーディア，インク ミオシンモジュレーターによる治療方法
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843A (zh) 2020-11-19 2022-05-20 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
EP4249474A4 (en) 2020-11-20 2024-04-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. TRIAZINDIONE DERIVATIVE, MANUFACTURING PROCESS THEREOF AND APPLICATION THEREOF IN MEDICINE
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
WO2022111498A1 (zh) 2020-11-24 2022-06-02 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤

Also Published As

Publication number Publication date
IL305628A (en) 2023-11-01
BR112023017461A2 (pt) 2023-09-26
CA3209557A1 (en) 2022-09-09
US11919909B2 (en) 2024-03-05
CN117083275A (zh) 2023-11-17
AU2022229390A1 (en) 2023-09-21
JP2024508526A (ja) 2024-02-27
KR20240015622A (ko) 2024-02-05
CL2023002616A1 (es) 2024-02-02
EP4301760A1 (en) 2024-01-10
AR125026A1 (es) 2023-05-31
WO2022187501A1 (en) 2022-09-09
US20220306642A1 (en) 2022-09-29
TW202302594A (zh) 2023-01-16

Similar Documents

Publication Publication Date Title
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
MX2022014312A (es) Inhibidores de sarcomero cardiaco.
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12021550400A1 (en) Cardiac sarcomere inhibitors
MX2021009764A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
MX2023004745A (es) 1,4-diazepanonas biciclicas y sus usos terapeuticos.
MX2021011286A (es) Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.
MX2021012278A (es) Azinas condensadas para la modulacion de ep300 o cbp e indicaciones de estos.
MX2023012907A (es) Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3).
MX2021012105A (es) Compuestos de pirrol.
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
MX2023007467A (es) Derivados de indol utiles en el tratamiento de afecciones asociadas con cgas.
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
JOP20220085A1 (ar) مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CR20230218A (es) Nuevos derivados de indazol acetileno
WO2023141432A3 (en) Apol1 inhibitors and methods of use
WO2022206730A8 (zh) 嘧啶并吡嗪酮化合物及其用途
MX2022016516A (es) Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso.
MX2023002068A (es) Nuevos compuestos que tienen actividad inhibidora sobre el receptor de prostaglandina e2 y usos de los mismos.
WO2022104153A3 (en) Compounds and methods for treating viral infections